Comparison of Efficacy of Topical Clobetasol Propionate 0.05% and Topical Tacrolimus 0.1% in the Treatment of Lichen Planus
Clicks: 2
ID: 311569
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #195 of 254 articles by views in Yemen Journal of Medicine
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background: Lichen planus (LP) is a papulosquamous cutaneous disorder that manifests as intensely itchy violaceous flat-topped polygonal papules and plaques. To compare the efficacy of topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in the treatment of LP.
Methods: This prospective Comparative Study was conducted at the Dermatology Department, Services Institute of Medical Sciences (SIMS)/Services Hospital, Lahore, from May 1, 2022, to April 30, 2023. Ethical approval was obtained from the institutional review board at the Department of Dermatology, SIMS/Services Hospital, Lahore. A total of 80 patients were selected after fulfilling the selection criteria. The study participants were placed into two groups, A and B. In group A, the patients were advised to use the topical application of clobetasol propionate (0.05%) ointment twice daily. In group B, tacrolimus ointment (0.1%) was used twice daily. Treatment response was assessed at 3 weeks, and then finally efficacy was evaluated at 6 weeks.
Results: Treatment efficacy was observed in 34 patients (42.5%). Group A (Clobetasol) demonstrated a significantly higher efficacy of 55% compared to 30% in Group B (Tacrolimus; p = 0.024).
Conclusions: The 0.05% clobetasol propionate topical formulation demonstrated superior efficacy in treating LP compared to 0.1% topical tacrolimus. Further validation of these findings through large-scale clinical trials is warranted.
| Reference Key |
chattha2026comparison
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ayesha Arshad Chattha, Saadiya Siddiqui, Faria Asad, Shahbaz Aman |
| Journal | Yemen Journal of Medicine |
| Year | 2026 |
| DOI |
10.63475/yjm.v4i2.0185
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.